Compare CZWI & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CZWI | MDWD |
|---|---|---|
| Founded | 1938 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.8M | 181.1M |
| IPO Year | 2006 | 2013 |
| Metric | CZWI | MDWD |
|---|---|---|
| Price | $21.02 | $12.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | 35.4K | ★ 71.5K |
| Earning Date | 04-27-2026 | 05-20-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | ★ 8.96 | N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.02 | $48.92 |
| Revenue Next Year | $9.42 | $35.04 |
| P/E Ratio | $41.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.61 | $12.61 |
| 52 Week High | $24.43 | $20.30 |
| Indicator | CZWI | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 46.51 | 38.74 |
| Support Level | $20.32 | N/A |
| Resistance Level | $21.69 | $14.93 |
| Average True Range (ATR) | 0.46 | 0.41 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 79.37 | 23.89 |
Citizens Community Bancorp Inc is a bank holding company that offers traditional community banking services to businesses, Agricultural operators, and consumers, including one-to-four-family residential mortgages. it also offers a variety of loan products including commercial real estate loans, commercial and industrial (C&I) loans, agricultural real estate loans, agricultural operating loans, residential mortgages, home equity lines-of-credit, and consumer loans and offers deposit products through its branches, including demand deposits, various savings and money-market accounts and certificates of deposit. The company's sources of funds are deposits; amortization, prepayments, and maturities of outstanding loans; other short - term investments; and funds provided from operations.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.